Laigo Bio closes €17M seed to advance SureTACs

📰 The Next Web AI

Laigo Bio raises €17M seed to develop SureTACs platform for drug discovery

intermediate Published 27 Mar 2026

Action Steps

Understand the limitations of conventional drug discovery methods
Learn about the SureTACs platform and its approach to targeting membrane proteins
Explore the potential applications of this technology in biotech and pharmaceutical industries

Who Needs to Know This

Biotech and pharmaceutical teams can benefit from this advancement in drug discovery, as it may lead to new treatment options for various diseases

Key Insight

💡 SureTACs platform targets membrane proteins by engineering them out of existence, rather than blocking them